Generic Antiepileptic Drug Substitution in Epilepsy Treatment

Generic substitution of antiepileptic drugs (AEDs) has emerged as a critical component of healthcare policy in many regions, driven by the need to contain costs and expand access to therapy. Generics are required to meet regulatory criteria for bioequivalence with brand-name counterparts, yet subtle variations in formulation, excipient profiles and pharmacokinetic parameters can influence therapeutic performance. In epilepsy, where small fluctuations in plasma concentration may precipitate seizure recurrence or adverse effects, substitution demands careful clinical consideration. Patient and clinician confidence hinges on robust pharmacovigilance, consistent drug supply and transparent communication regarding potential risks and benefits. Globally, variability in regulatory standards and healthcare infrastructure amplifies challenges: some settings experience frequent shortages, while others raise concerns over generic quality and regulatory oversight. Strategies to mitigate risk include therapeutic drug monitoring, patient education, pharmacist-led counselling and international harmonisation of bioequivalence criteria. Emerging evidence highlights both the promise of generics to improve affordability and the necessity for vigilance to preserve seizure control and patient safety.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Generic Antiepileptic Drug Substitution in Epilepsy Treatment publication trend

The graph below shows the total number of articles in generic antiepileptic drug substitution in epilepsy treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Bioequivalence: Demonstration that a generic product’s rate and extent of absorption match those of the reference formulation within predefined limits.

Narrow therapeutic index: A characteristic of drugs for which small differences in dose or blood concentration may lead to therapeutic failure or toxicity.

Excipient: An inactive substance formulated alongside the active drug ingredient, which may affect absorption, tolerability or stability.

Therapeutic equivalence: Clinical assurance that two formulations produce the same therapeutic outcome in terms of efficacy and safety.

Interchangeability: The designation that one medicinal product may be substituted for another with an expectation of the same clinical effect and safety profile.

References

1. Effects of Valproic Acid Supply Shortage on Pharmacy Operations in a Region of Japan. Cureus (2024).
2. Analyzing excipient-related adverse events in antiseizure drug formulations. Epilepsy Research (2022).
3. Evaluating Therapeutic Equivalence of Generic and Original Levetiracetam in Patients with Epilepsy: A Retrospective Study. Neurology International (2022).